Mereo BioPharma Group Statistics
Share Statistics
Mereo BioPharma Group has 154.73M shares outstanding. The number of shares has increased by 10.48% in one year.
| Shares Outstanding | 154.73M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -10.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 142.11M |
| Failed to Deliver (FTD) Shares | 1.35K |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 7.05M, so 4.56% of the outstanding shares have been sold short.
| Short Interest | 7.05M |
| Short % of Shares Out | 4.56% |
| Short % of Float | 5.13% |
| Short Ratio (days to cover) | 7.88 |
Valuation Ratios
The PE ratio is -51.7 and the forward PE ratio is -136.67.
| PE Ratio | -51.7 |
| Forward PE | -136.67 |
| PS Ratio | 152.33 |
| Forward PS | 14.1 |
| PB Ratio | 30.14 |
| P/FCF Ratio | -70.69 |
| PEG Ratio | n/a |
Enterprise Valuation
Mereo BioPharma Group has an Enterprise Value (EV) of 1,523.30B.
| EV / Earnings | -51696.43 |
| EV / Sales | 152328.71 |
| EV / EBITDA | -58462.05 |
| EV / EBIT | -53606.67 |
| EV / FCF | -70682.9 |
Financial Position
The company has a current ratio of 6.72, with a Debt / Equity ratio of 0.09.
| Current Ratio | 6.72 |
| Quick Ratio | 6.72 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8 |
| Cash Flow / Debt | -4.81 |
| Interest Coverage | -9.86 |
Financial Efficiency
Return on equity (ROE) is -0.58% and return on capital (ROIC) is -49.41%.
| Return on Equity (ROE) | -0.58% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -49.41% |
| Revenue Per Employee | 303.03K |
| Profits Per Employee | -892.91K |
| Employee Count | 33 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -532.00K |
| Effective Tax Rate | 0.02 |
Stock Price Statistics
The stock price has increased by -0.97% in the last 52 weeks. The beta is 0.97, so Mereo BioPharma Group's price volatility has been higher than the market average.
| Beta | 0.97 |
| 52-Week Price Change | -0.97% |
| 50-Day Moving Average | 3.69 |
| 200-Day Moving Average | 3.76 |
| Relative Strength Index (RSI) | 33.69 |
| Average Volume (20 Days) | 881.36K |
Income Statement
In the last 12 months, Mereo BioPharma Group had revenue of 10.00M and earned -29.47M in profits. Earnings per share was -0.04.
| Revenue | 10.00M |
| Gross Profit | 7.43M |
| Operating Income | -28.42M |
| Net Income | -29.47M |
| EBITDA | -26.06M |
| EBIT | -28.42M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
The company has 57.42M in cash and 5.95M in debt, giving a net cash position of 51.47M.
| Cash & Cash Equivalents | 57.42M |
| Total Debt | 5.95M |
| Net Cash | 51.47M |
| Retained Earnings | -419.63M |
| Total Assets | 88.75M |
| Working Capital | 72.52M |
Cash Flow
In the last 12 months, operating cash flow was -21.13M and capital expenditures -419.00K, giving a free cash flow of -21.55M.
| Operating Cash Flow | -21.13M |
| Capital Expenditures | -419.00K |
| Free Cash Flow | -21.55M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 74.26%, with operating and profit margins of -284.16% and -294.66%.
| Gross Margin | 74.26% |
| Operating Margin | -284.16% |
| Pretax Margin | -299.98% |
| Profit Margin | -294.66% |
| EBITDA Margin | -260.56% |
| EBIT Margin | -284.16% |
| FCF Margin | -215.51% |
Dividends & Yields
MREO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.31% |
| FCF Yield | -4.55% |
Analyst Forecast
The average price target for MREO is $7, which is 128.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 128.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 13.9 |
| Piotroski F-Score | 3 |